You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
Moodys
Johnson and Johnson
Baxter
Harvard Business School

Last Updated: July 2, 2020

DrugPatentWatch Database Preview

Details for Patent: 4,525,358


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 4,525,358
Title: 2-[4-(Diphenylmethyl)-1-piperazinyl]-acetic acids and their amides
Abstract:New 2-[4-(diphenylmethyl)-1-piperazinyl]-acetic acids, their amides and their salts, processes for the preparation thereof and therapeutic compositions. These compounds have the formula ##STR1## wherein Y=--OH or --NH.sub.2 ; X and X'=H, halogen, alkoxy or trifluoromethyl; m=1 or 2 and n=1 or 2. The amides of the 2-[4-(diphenylmethyl)-1-piperazinyl]-acetic acids are prepared either by reacting a 1-(diphenylmethyl)-piperazine with an omegahaloacetamide, or by reacting an alkali metal salt of an omega-[4-(diphenylmethyl)-1-piperazinyl]-alkanol with a 2-haloacetamide, or yet by reacting ammonia with a halide or alkyl ester of a 2-[4-(diphenylmethyl)-1-piperazinyl]-acetic acid, whereas the 2-[4-(diphenylmethyl)-1-piperazinyl]-acetic acids are prepared by hydrolyzing the corresponding amide or lower alkyl ester. These compounds have in particular an antiallergic, spasmolytic and antihistaminic activity.
Inventor(s): Baltes; Eugene (Rhode-St.Genese, BE), de Lannoy; Jean (Brussels, BE), Rodriguez; Ludovic (Brussels, BE)
Assignee: UCB Pharmaceuticals, Inc. (Dover, DE)
Application Number:06/496,489
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 4,525,358

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 4,525,358

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom8103768Feb 06, 1981
United Kingdom8110990Apr 08, 1981

International Family Members for US Patent 4,525,358

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 8140   Start Trial
Australia 544066   Start Trial
Australia 8023182   Start Trial
Bosnia and Herzegovina 97198   Start Trial
Bosnia and Herzegovina 97199   Start Trial
Canada 1199918   Start Trial
Cyprus 1307   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Mallinckrodt
Colorcon
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.